Poseida Therapeutics Stock Performance
| PSTX Stock | USD 9.33 0.05 0.53% |
Poseida Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 2.78, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Poseida Therapeutics will likely underperform. Use Poseida Therapeutics skewness, day typical price, and the relationship between the downside variance and daily balance of power , to analyze future returns on Poseida Therapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Poseida Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Poseida Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.53) | Five Day Return 244.28 | Year To Date Return 176.04 | Ten Year Return (39.22) | All Time Return (39.22) |
1 | Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with RelapsedRefractory Multiple Myeloma at 21... | 09/05/2024 |
2 | Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated R... | 09/27/2024 |
3 | Insider Trading | 10/14/2024 |
4 | Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema | 10/24/2024 |
5 | Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 | 11/07/2024 |
6 | Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Marketscreener.com | 11/21/2024 |
7 | Wall Street Analysts Think Poseida Therapeutics Could Surge 49.25 percent Read This Before Placing a Bet | 11/27/2024 |
| Begin Period Cash Flow | 81.4 M |
Poseida |
Poseida Therapeutics Relative Risk vs. Return Landscape
If you would invest 286.00 in Poseida Therapeutics on August 30, 2024 and sell it today you would earn a total of 647.00 from holding Poseida Therapeutics or generate 226.22% return on investment over 90 days. Poseida Therapeutics is currently generating 3.7224% in daily expected returns and assumes 29.111% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Poseida, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Poseida Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Poseida Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Poseida Therapeutics, and traders can use it to determine the average amount a Poseida Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1279
| Best Portfolio | Best Equity | |||
| Good Returns | PSTX | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 29.11 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.72 actual daily | 74 74% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Poseida Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Poseida Therapeutics by adding it to a well-diversified portfolio.
Poseida Therapeutics Fundamentals Growth
Poseida Stock prices reflect investors' perceptions of the future prospects and financial health of Poseida Therapeutics, and Poseida Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Poseida Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 766.1 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Price To Earning | 214.00 X | ||||
| Price To Book | 10.48 X | ||||
| Price To Sales | 6.03 X | ||||
| Revenue | 64.7 M | ||||
| Gross Profit | (22.41 M) | ||||
| EBITDA | (109.04 M) | ||||
| Net Income | (123.43 M) | ||||
| Cash And Equivalents | 142.56 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 85.42 M | ||||
| Debt To Equity | 1.39 % | ||||
| Current Ratio | 3.69 X | ||||
| Book Value Per Share | 0.90 X | ||||
| Cash Flow From Operations | (92.17 M) | ||||
| Earnings Per Share | (0.63) X | ||||
| Market Capitalization | 909.36 M | ||||
| Total Asset | 273.88 M | ||||
| Retained Earnings | (594.29 M) | ||||
| Working Capital | 155.16 M | ||||
| Current Asset | 10.59 M | ||||
| Current Liabilities | 5.1 M | ||||
About Poseida Therapeutics Performance
Evaluating Poseida Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Poseida Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Poseida Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 283.53 | 252.02 | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (1.19) | (1.13) |
Things to note about Poseida Therapeutics performance evaluation
Checking the ongoing alerts about Poseida Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Poseida Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Poseida Therapeutics is way too risky over 90 days horizon | |
| Poseida Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (22.41 M). | |
| Poseida Therapeutics currently holds about 142.56 M in cash with (92.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Poseida Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Wall Street Analysts Think Poseida Therapeutics Could Surge 49.25 percent Read This Before Placing a Bet |
- Analyzing Poseida Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Poseida Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Poseida Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Poseida Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Poseida Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Poseida Therapeutics' stock. These opinions can provide insight into Poseida Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.